Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 6/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL849440 | 0.93 | PTH1R (0.48) | PTH1RTACR1TAOK1CALCRLHTR6 | |
| SCHEMBL848117 | 0.91 | PTH1R (0.59) | PTH1RTACR1TAOK1CALCRLATM | |
| SCHEMBL849380 | 0.89 | PTH1R (0.51) | PTH1RTACR1TAOK1CALCRLADRA1D | |
| SCHEMBL847147 | 0.84 | TACR1 (0.48) | PTH1RTACR1TAOK1CALCRLADRA1D | |
| SCHEMBL849558 | 0.84 | PTH1R (0.47) | PTH1RTACR1TAOK1 | |
| SCHEMBL848076 | 0.82 | PTH1R (0.55) | PTH1RTACR1TAOK1 | |
| SCHEMBL849871 | 0.82 | PTH1R (0.47) | PTH1RTACR1TAOK1CALCRL | |
| SCHEMBL848872 | 0.82 | PTH1R (0.47) | PTH1RTACR1TAOK1CALCRL | |
| SCHEMBL849870 | 0.82 | PTH1R (0.47) | PTH1RTACR1TAOK1CALCRL | |
| SCHEMBL847224 | 0.81 | PTH1R (0.48) | PTH1RTACR1TAOK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PTH1R 1869/4885TACR1 141/4885TAOK1 915/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PTH1R 1869/4885TACR1 141/4885TAOK1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.